Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Evaluation of the Tolerability and Feasibility of Combining 5-Amino-Levulinic Acid (5-ALA) With Carmustine Wafers (Gliadel) in the Surgical Management of Primary Glioblastoma (GALA-5 Trial)

NCT01310868 is registered in ClinicalTrials.gov with University College, London as lead sponsor.

NCT NCT01310868
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01310868 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Evaluation of the Tolerability and Feasibility of Combining 5-Amino-Levulinic Acid (5-ALA) With Carmustine Wafers (Gliadel) in the Surgical Management of Primary Glioblastoma (GALA-5 Trial)
Lead sponsor
University College, London
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2011
Completion date
March 31, 2015
Enrollment
59 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma